BACKGROUND: Neuroinflammation is an important pathological process for almost all acquired neurological diseases. Microglial cells play a critical role in neuroinflammation. We determined whether lidocaine, a local anesthetic with anti-inflammatory property, protected microglial cells and attenuated cytokine production from activated microglial cells. METHODS: Mouse microglial cultures were incubated with or without 1 g/mL lipopolysaccharide and 10 U/mL interferon ␥ (IFN␥) for 24 hours in the presence or absence of lidocaine for 1 hour started at 2, 3, or 4 hours after the onset of lipopolysaccharide and IFN␥ stimulation. Lactate dehydrogenase release and cytokine production were determined after the cells were stimulated by lipopolysaccharide and IFN␥ for 24 hours. RESULTS: Lidocaine dose-dependently reduced lipopolysaccharide and IFN␥-induced microglial cell injury as measured by lactate dehydrogenase release. This effect was apparent with lidocaine at 2 g/mL (30.3% Ϯ 5.8% and 23.1% Ϯ 9.7%, respectively, for stimulation alone and the stimulation in the presence of lidocaine, n ϭ 18, P ϭ 0.025). Lidocaine applied at 2, 3, or 4 hours after the onset of lipopolysaccharide and IFN␥ stimulation reduced the cell injury. This lidocaine effect was not affected by the mitochondrial K ATP channel inhibitor 5-hydroxydecanoate. Similar to lidocaine, QX314, a permanently charged lidocaine analog that usually does not permeate through the plasma membrane, reduced lipopolysaccharide and IFN␥-induced microglial cell injury. QX314 also attenuated the stimulation-induced interleukin-1␤ production. CONCLUSIONS: Delayed treatment with lidocaine protects microglial cells and reduces cytokine production from these cells. These effects may involve action site(s) on the cell surface. (Anesth Analg 2012;114:856 -61) Hae-Jeong Jeong is currently affiliated with the
M icroglial cells participate in host defense and inflammation in the brain. 1 They respond to various stimulants including bacterial products to produce cytokines and other factors to modulate/induce host defense and inflammation in the central nervous system. [1] [2] [3] The end results of this process may include death and dysfunction of brain cells, including microglial cells. Although neuroinflammation has been considered a major pathological process for many human neurological diseases, such as Alzheimer disease, 1, 4 knowledge on how to regulate microglial cell functions and preserve their structural integrity is scarce.
Lidocaine is a local anesthetic and has been shown to have significant anti-inflammatory property. 5, 6 It also provides neuroprotection when it is used during brain ischemia in rats. 7, 8 Lidocaine used immediately at the onset of simulated reperfusion also reduces neuronal death in rat hippocampal slice cultures. 9 However, it is not known whether lidocaine can protect other brain cells, such as microglial cells. The effects of lidocaine on the production of neuroinflammation mediators from microglial cells are not known. We hypothesized that lidocaine can protect microglial cells and inhibit cytokine production from activated microglial cells. We tested this hypothesis by using mouse microglial cells stimulated with lipopolysaccharide plus interferon ␥ (IFN␥). This method of stimulation is commonly used to in vitro simulate endotoxemia and the subsequent inflammation. 3, 10 
METHODS Materials
C8-B4 cells (CRL-2540 TM ), a microglial clone isolated from mouse cerebellum, were purchased from the American Type Culture Collection (Manassas, VA). Lipopolysaccharide from Escherichia coli 0111:B4 and other chemicals except for those described below were obtained from Sigma-Aldrich (St. Louis, MO). Heat inactivated fetal bovine serum, recombinant rat IFN␥ produced from E. coli and Alexa Fluor 488 goat antimouse immunoglobulin (Ig)G antibody were obtained from Invitrogen Corporation (Carlsbad, CA). Lactate dehydrogenase (LDH) activity assay kit was from Clontech Laboratory (La Jolla, CA). ELISA kits for measuring rat interleukin 1␤ (IL-1␤) and tumor necrosis factor ␣ (TNF␣) were purchased from R&D Systems (Minneapolis, MN). Lidocaine was from Dai-Han Pharm. Co., LTD (Yeongdeungpo-gu, Seoul, South Korea). Normal goat serum was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and mouse monoclonal anti-ionized calcium binding adaptor molecule 1 (Iba1) antibody was purchased from Abcam Inc. (Cambridge, MA). Hoechst solution was from Thermo Scientific (Waltham, MA).
Cell Culture
C8-B4 cells were cultured as we previously described. 3, 11 Briefly, they were cultured in Dulbecco's Modified Eagle's Medium containing 4 mM l-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate and supplemented with 10% heat inactivated fetal bovine serum, 100 U/mL penicillin, and 100 pg/mL streptomycin in a humidified atmosphere of 95% air, 5% CO 2 at 37°C. The medium was changed every 3 days. The cells were plated at a density of 2.5 to 3 ϫ 10 5 cells/mL on 6-well culture plates for various experiments.
Immunocytochemistry
To determine the purity of our cultures, we examined the expression of Iba1, a microglia-specific protein, in these cells. C8-B4 cells were fixed with ice-cold methanol for 5 minutes. After being rinsed with ice-cold phosphatebuffered saline (PBS) twice, cells were incubated in PBS containing 0.25% Triton X-100 for 10 minutes. They were then washed with PBS 3 times for 5 minutes and incubated with 5% normal goat serum in PBS for 30 minutes. Cells were incubated with the anti-Iba1 antibody at a dilution of 1:50 for 1 hour at room temperature. They were rinsed with PBS and were incubated in Alexa Fluor 488 goat antimouse IgG antibody at a dilution of 1:250 for 1 hour at room temperature. All cells were counterstained using 1 g/mL of Hoechst solution. They were rinsed with PBS, mounted with mounting medium, and observed under a fluorescence microscope.
Trypan Blue Exclusion Assay
To determine the viability of the cells under control conditions, we detached the cells from culture plates by incubation with 0.25% trypsin for 3 minutes at 2, 3, or 4 days after they were plated in the 6-well plates. The cells were then incubated in 0.04% trypan blue for 5 minutes at room temperature. Trypan blue stained or unstained cells were counted under a microscope with the use of a hemocytometer as we described previously. 12 Cell Stimulation and Exposure to Lidocaine and Various Chemicals Cells were exposed to 1 g/mL lipopolysaccharide and 10 U/mL IFN␥ for 24 hours at 24 hours after the cells were plated. This incubation condition induced a significant LDH release in our previous study. 3, 11 In one set of experiments, lidocaine at 2, 10, or 20 g/mL was applied for 1 hour at 2 hours after the onset of lipopolysaccharide and IFN␥ stimulation. In another experiment, 20 g/mL lidocaine was incubated with the cells for 1 hour at 3 or 4 hours after the onset of lipopolysaccharide and IFN␥ stimulation. QX314, a permanently charged lidocaine analog, was added to the medium to make the final concentration at 25 g/mL (73 M that was the same molar concentration as 20 g/mL lidocaine) for 1 hour at 2 hours after the addition of lipopolysaccharide and IFN␥. The mitochondrial K ATP channel inhibitor 5-hydroxydecanoate (5-HD) was added 10 minutes before the application of lidocaine to make the final concentration 100 M in the medium and was incubated with the cells for 70 minutes. After the completion of incubation with lidocaine, QX314, or 5-HD, the incubation solutions were replaced with fresh medium that did not contain these reagents but still included lipopolysaccharide and IFN␥. A similar procedure (incubation medium changing) was used in the other experimental groups in the same set of experiments.
Lactate Dehydrogenase Activity Assay
As we described before, 11 the culture medium was harvested at 24 hours after the onset of lipopolysaccharide and IFN␥ stimulation and was centrifuged at 1000 g for 10 minutes. One hundred microliters cell-free supernatant was transferred to 96-well plates and incubated with the same amount of reaction mixture from the LDH detection kit. LDH activity was measured on the basis of a colorimetric assay. The absorbance of samples was read at 492 nm with the reference wavelength of 655 nm in a spectrophotometry (Bio-Rad Laboratories). Background absorbance from the cell-free buffer solution was subtracted from all absorbance measurements. After removal of the culture medium from cells, cells were lysed with 1% triton X-100. The percentage of LDH released to culture medium in total LDH was calculated: 100 ϫ LDH in the culture medium/(LDH in the culture medium ϩ intracellular LDH released by triton X-100).
Quantification of IL-1␤ and TNF␣
Culture medium was centrifuged at 1000 g for 10 minutes at 4°C. The supernatant was then assayed by ELISA kits for measuring rat IL-1␤ and TNF␣ according to the manufacturer's instructions.
Data Analysis
Data are expressed as means Ϯ SD (n Ն6 for each experimental condition). They were analyzed by 1-way analysis of variance followed by the Tukey test for post hoc analysis after confirmation of normal distribution of the data or by Kruskal-Wallis analysis of variance on ranks followed by the Dunn's test when the data are not normally distributed. A P value Ͻ0.05 was considered statistically significant. All statistical analyses were performed with the SigmaStat (Systat Software, Inc., Point Richmond, CA). Figure 1 , all cells that were stained by Hoechst were also positively stained by the anti-Iba1 antibody in our culture. Because Hoechst is a fluorescent DNA dye and should stain all cells, this result suggests that all cells in our culture have microglial phenotype.
RESULTS

As shown in
As we reported previously, 11 the combination of lipopolysaccharide and IFN␥ increased LDH release from the microglial cells. Because LDH release from cells may require cell plasma membrane damage, this result suggests that lipopolysaccharide and IFN␥ cause microglial injury. This injury was dose-dependently attenuated by lidocaine applied at 2 hours after the onset of lipopolysaccharide and IFN␥ stimulation. This protection was already apparent with lidocaine at 2 g/mL (30.3% Ϯ 5.8% and 23.1% Ϯ 9.7%, respectively, for stimulation alone and the stimulation in the presence of lidocaine, n ϭ 18, P ϭ 0.025) ( Fig.  2A ). Application of 20 g/mL lidocaine at 3 or 4 hours after the onset of lidocaine also reduced lipopolysaccharide and IFN␥-induced microglial cell injury (Fig. 2B) .
The protective effect of lidocaine was not affected by 5-HD (Fig. 3A ). Similar to lidocaine, 25 g/mL QX314 also attenuated lipopolysaccharide and IFN␥-induced cell injury (Fig. 3B ).
Lipopolysaccharide and IFN␥ increased the production of IL-1␤ and TNF␣ from the microglial cells. Application of QX314 attenuated the lipopolysaccharide and IFN␥induced increase of IL-1␤ but did not affect the increase of TNF␣ (Fig. 4) .
Because there was a high percentage of extracellular LDH in our microglial cell cultures under control conditions, we used trypan blue exclusion assay to determine whether these cells were injured. As shown in Figure 5 , cell numbers were increased with the time in culture. This increase was stopped on the third day in culture because they were confluent. However, trypan blue-positive cells were not increased with the time in culture. Of note, LDH release assay performed in other experiments occurred during the second day after the cells were plated in the 6-well plates.
DISCUSSION
Our results clearly show that delayed treatment with lidocaine attenuates lipopolysaccharide and IFN␥-induced microglial injury. Lidocaine has been shown to provide neuroprotection in animal studies. 7, 8 Our finding adds a novel mechanism for this neuroprotective effect because microglial cells are brain cells and protection of microglial cells may reduce secondary injury to other brain cells, such The mouse C8 -B4 microglial cells were incubated with 1 g/mL LPS and 10 U/mL IFN␥ for 24 hours. Cells were exposed to 2, 10, or 20 g/mL lidocaine for 1 hour at 2 hours after the initiation of the LPS and IFN␥ stimulation. Cell injury was quantified by lactate dehydrogenase (LDH) release assay. Results are mean Ϯ SD (n ϭ 15 to 18). B, Time window of delayed isoflurane treatment. The mouse C8 -B4 microglial cells were incubated with 1 g/mL LPS and 10 U/mL IFN␥ for 24 hours. Cells were exposed to 20 g/mL lidocaine for 1 hour at 3 or 4 hours after the initiation of the LPS and IFN␥ stimulation. Results are mean Ϯ SD (n ϭ 6 to 17). *P Ͻ 0.05 in comparison with control. P Ͻ 0.05 in comparison with LPS plus IFN␥ only.
as neurons, due to the release of intracellular toxic chemicals from microglial cells. Our results indicate that lidocaine at 2 g/mL is protective. It has been proposed that the plasma concentrations of lidocaine at 2 to 5 g/mL are an accepted therapeutic range for its effects, such as suppression of seizures. 13 Although the brain lidocaine concentrations corresponding to this plasma therapeutic range are not known, our findings suggest that protection of microglial cells by lidocaine may occur at clinically relevant concentrations. In our study, the latest application of lidocaine was at 4 hours after the onset of lipopolysaccharide and IFN␥ stimulation. This delayed treatment also attenuated lipopolysaccharide and IFN␥-induced microglial injury. Further delay of the treatment was not performed because of the concern that culture medium change that is needed for removal of lidocaine at a very later time point may affect the cell response to lipopolysaccharide and IFN␥ and will decrease the amount of LDH in the culture medium used for LDH release assay.
The protective effects of lidocaine on microglial cells may be mediated by cell surface target(s) because extracellular application of QX314 also induces a similar protection. QX314 is a permanently charged lidocaine analog whose charge does not appear to be affected by pH. 14, 15 Thus, QX314 should not be able to permeate through the plasma membrane. Consistent with this possibility, we and other people have shown that intracellular, but not external, application of QX314 can affect the glutamate transporter type 3 activity and N-methyd-aspartate receptor signaling. 16, 17 The effects of lidocaine on glutamate transporter type 3 and N-methy-d-aspartate receptor signaling are shown to be mediated by intracellular protein kinase C. 16, 17 Also, our results show that lidocaine's effects were not inhibited by 5-HD, suggesting that mitochondrial K ATP channels may not be involved in lidocaine's protection. Mitochondrial K ATP channels may be involved in lidocaine's protection of cytokine-induced endothelial cell injury. 18 The failed inhibition of lidocaine's protection by 5-HD as observed in this study is consistent with the possibility that lidocaine's effects may be through cell surface target(s).
Lidocaine has been shown to reduce lipopolysaccharideinduced cytokine release in rat lungs and adenosine triphosphate-induced cytokine release from rat microglial cultures. 5, 19 Consistent with these findings, we showed here that QX314 attenuated lipopolysaccharide and IFN␥-induced IL-1␤ release from mouse microglial cells. Because production of cytokines is an indicator of microglial cell activation, this result suggests that QX314/lidocaine can reduce the microglial activation caused by lipopolysaccharide and IFN␥. Previous studies show that IL-1␤ and TNF␣ release from rat lungs stimulated by lipopolysaccharide or from microglial Figure 3 . Protective effects of lidocaine or QX314 on lipopolysaccharide (LPS) and interferon ␥ (IFN␥)-induced cell injury. The mouse C8 -B4 microglial cells were incubated with 1 g/mL LPS and 10 U/mL IFN␥ for 24 hours. Cells were exposed to 20 g/mL lidocaine or 25 g/mL QX314 for 1 hour at 2 hours after the initiation of the LPS and IFN␥ stimulation. cultures stimulated by ATP is inhibited by lidocaine. 5, 19 However, TNF␣ release in our study is not affected by QX314. The reasons for the selective effect of QX314 on IL-1␤ are not known from our study. Further studies are needed to reveal the mechanisms for this interesting finding.
Cytokines are important mediators for inflammation that can lead to cell injury. The reduction of lipopolysaccharide and IFN␥-induced IL-1␤ release by QX314 may be a mechanism for its protective effects on microglial cells. Consistent with this proposal, direct application of cytokines has been shown to induce cell injury. 18 We plated the same number of cells in each culture well and harvested the culture medium for cytokine measurement after the cells were stimulated by lipopolysaccharide plus IFN␥ for 24 hours. We did not normalize the cytokine results by the final number of cells or protein amount at the end of the study because cytokines should be produced at all times during the 24-hour incubation, and it is difficult to determine at which time points cell number or protein amount should be used to normalize these cytokine data. In addition, assuming that the change in direction of intact cell numbers at the end of the 24-hour incubation is opposite to that of LDH release data among different experimental conditions (i.e., the cultures exposed to lipopolysaccharide and IFN␥ alone have the highest LDH release and lowest intact cell number), normalization of the cytokine data by the final number of intact cells at the end of the incubation should increase the difference among the groups but should not alter the change in direction shown in Figure 4 .
Our findings may have significant implications. Sepsis or infections are common clinical entities. Neuroinflammation and activation of brain cells that are involved in neuroinflammation are proposed to participate in the pathophysiology of a broad spectrum of diseases, including stroke and neurodegenerative diseases. Preservation of brain cells and modulation of neuroinflammation participating cells under these clinical situations will obviously be beneficial. Delayed treatment with lidocaine as shown in this study may be a useful approach for this purpose.
Interestingly, in contrast to the neuroprotective effects reported in humans and animals, 7, 8, 20, 21 lidocaine has also been reported to induce neurotoxicity. Cauda equine syndrome and transient neurological symptoms occur after spinal anesthesia with lidocaine. 22 Lidocaine at very high systemic concentrations can cause neurotoxicity, such as seizure, in humans. A systemic subconvulsive dose of lidocaine induces neuronal death in rat brain. 23 These neurotoxic effects are very likely caused by high local concentrations in neural tissues. It is not known whether the protective effects of lidocaine at concentrations within its therapeutic window on microglia as shown in this study have an implication in lidocaine-induced neurotoxicity.
Our study has limitations. We used microglial cell cultures to obtain cell-specific effects. It is not appropriate to directly extrapolate our findings to more complex biological systems, such as in vivo conditions. Also, we have not identified which cell surface target(s) may be involved in the lidocaine effect. Further studies are needed to reveal the molecular mechanisms for this lidocaine effect. Finally, a high percentage (ϳ20%) of total LDH was in the culture medium of the control cells. This percentage is very similar to that reported in our previous study also using C8-B4 cells. 24 Other than our data, studies reporting LDH release in these cells under control conditions have not been identified in the literature. The mechanisms for this high percentage of extracellular LDH in control cells are not known yet. Since trypan blue positive cells were not increased over the time in culture under the control conditions, cell injury or sick cells may not be the reason for the high extracellular LDH fraction in control cells.
In conclusion, our study has shown that delayed treatment with lidocaine attenuates lipopolysaccharide and IFN␥-induced microglial cell activation and injury. These effects may be mediated by cell surface target(s).
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